May 7, 2024
amsterdam, netherlands – Argenx (Euronext & Nasdaq: ARGX), a global immunology company dedicated to improving the lives of people suffering from severe autoimmune diseases, today announced that members of its executive team will be presenting at the 2024 BofA Securities Healthcare Conference. He announced that he would be participating in a fireside chat. Tuesday, May 14, 2024, 10am Pacific Time, Las Vegas, NV.
A live webcast of the hearth chat can be accessed from the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 90 days after the fireside chat.
About Argenx
argenx is a global immunology company dedicated to improving the lives of people living with severe autoimmune diseases. Through its Immunology Innovation Program (IIP), argenx partners with leading academic researchers to transform breakthrough advances in immunology into a world-class portfolio of novel antibody-based medicines. argenx develops and commercializes the first neonatal Fc receptor (FcRn) blocker approved in the US, Japan, Israel, EU, UK, Canada, and China. The company is evaluating efgartigimod in multiple serious autoimmune diseases and is advancing several early-stage experimental drugs within its therapeutic franchise. For more information, please visit www.argenx.com and follow us on LinkedIn, X/Twitter, Instagram, Facebook and YouTube.
For more information, please contact us below.
media:
ben petok
bpetok@argenx.com
Investor:
Alexandra Roy (USA)
aroy@argenx.com
Lynn Elton (EU)
lelton@argenx.com
